MEDICINES CO /DE
MEDICINES CO /DE (MDCO): 6 pipeline candidates · ~14 mo cash runway · 3 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
14.3 months
D/E -15.51 · 1% dilution
Lead: Phase 3
6 candidates
N/A
N/A
A transparent, data-derived signal for MEDICINES CO /DEacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$270.3M
Quarterly Burn
$60.7M
Runway
14.3 mo
Revenue
$0
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (6 candidates)
| Drug | Phase |
|---|---|
| aln-pcs02 | Preclinical |
| dovramilast | Phase 2 |
| inclisiran | Phase 3 |
| mdco-700 | — |
| moxidectin oral product | Phase 2 |
| tos-358 | Phase 1 |
Frequently asked questions
How many drug candidates are in MEDICINES CO /DE's pipeline?
MEDICINES CO /DE (MDCO) has 6 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is MEDICINES CO /DE's lead drug candidate?
MEDICINES CO /DE's most advanced tracked candidate is aln-pcs02 (Preclinical) for hypercholesterolemia.
What is MEDICINES CO /DE's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, MEDICINES CO /DE has approximately 14.3 months of cash runway.
Who is the CEO of MEDICINES CO /DE?
The Medicines Company is the chief executive officer of MEDICINES CO /DE (MDCO).
Get the full picture on MEDICINES CO /DE
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.